INmune Bio, Inc. reported significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe Alzheimer?s Disease treated with XPro for four weeks. Patients who received weekly XPro? treatment for four weeks had a statistically significant increase in Alpha wave frequency and power (p<0.05).

Reduced Alpha power is linked with cognitive decline and the progression of Alzheimer?s Disease. Alpha waves represent synchronized brain network activity that are essential for internal functions like mental arithmetic, short-term and working memory, and visual-spatial mental imagery exercises. In individuals with AD, Alpha wave power is diminished due to the breakdown of brain networks associated with degeneration.

The seven patient pilot study in patients with moderate to severe AD sought to evaluate the utility of EEG as a functional biomarker of target engagement in evaluating the effects of XPro? (XPro1595; pegipanermin), a next generation dominant-negative inhibitor of soluble TNF, in AD patients. These positive results support and add to the findings of the Phase 1 study in patients with AD that showed XPro?

treatment reduced biomarkers of inflammation and improved biomarkers of neurodegeneration, synaptic function and improved brain microstructure and promoted remyelination. The extent to which these biomarker changes impact cognition in patients with Early Alzheimer's Disease is currently being assessed in ongoing randomized, placebo-controlled Phase 2 trial. EEG, long considered a gold standard in objectively measuring brain activity, provides valuable insight into neural connectivity.

Neurological research has consistently highlighted a progressive decline in alpha band power and frequency in individuals with MCI and Alzheimer's disease. EEG's capability to assess brain function makes these findings particularly noteworthy for INmune Bio?s novel treatment strategy. The use of EEG as a biomarker for brain function and its potential as a regular measure in clinical trials was facilitated by Cumulus Neuroscience?s innovative, FDA approved, portable EEG device.